Search results
Results from the WOW.Com Content Network
Negative interim PET scan results probably result in a large increase in the overall survival compared to those with a positive interim PET scan result. [62] Current research evaluated whether Nivolumab can be used for the treatment of a Hodgkin's lymphoma. The evidence is very uncertain about the effect of Nivolumab for patients with a Hodgkin ...
A 2020 review of research on the use of PET for Hodgkin lymphoma found evidence that negative findings in interim PET scans are linked to higher overall survival and progression-free survival; however, the certainty of the available evidence was moderate for survival, and very low for progression-free survival. [11]
In 2015, about 4.3 million people had non-Hodgkin lymphoma, and 231,400 (5.4%) died. [4] [5] In the United States, 2.1% of people are affected at some point in their life. [2] The most common age of diagnosis is between 65 and 75 years old. [2] The five-year survival rate in the United States is 71%. [2]
>30% increase in 18F-FDG SUL peak, with >0.8 SUL units increase in tumor SUV peak from the baseline scan in pattern typical of tumor and not of infection/treatment effect. or Visible increase in the extent of 18F-FDG tumor uptake. or New 18F-FDG avid lesions which are typical of cancer and not related to treatment effect or infection.
The evidence is very uncertain about the effect of negative (= good prognosis) or positive (= bad prognosis) interim PET scan results for patients with a Hodgkin's lymphoma on the progression-free survival. Negative interim PET scan results may result in an increase in progression-free survival compared if the adjusted result was measured.
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
Stage IV: The lymphoma is in one or more organs beyond the lymphatic system, such as the liver, lungs, bone marrow, or cerebrospinal fluid. [2] A patient's stage may be determined through blood tests, bone marrow biopsy, chest X-rays, computed tomography (CT) scans, positron emission tomography (PET) scans, and magnetic resonance imaging (MRI).
median overall survival time of approximately 12–16 months, with five-year survival rate of approximately 26% and the long-term survival rate of approximately 4 - 5%. Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a ...